Presentation is loading. Please wait.

Presentation is loading. Please wait.

Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in.

Published by佛疋 项 Modified over 5 years ago

Similar presentations

Presentation on theme: "Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in."— Presentation transcript:

1 Presentation and progression of glioblastoma with PNET features in an adult patient.
Presentation and progression of glioblastoma with PNET features in an adult patient. A, a left frontoinsular enhancing tumor was identified at presentation and resected. Following concomitant temozolomide and radiation treatment, an intradural/extramedullary C7-T2 metastasis was identified and also resected. Following a course of pembrolizumab, a second intradural/extramedullary metastasis at T7-8 was resected. All tumors were glioblastoma with PNET features. B, mutational burden as detected by whole-exome DNA sequencing. Each tumor harbored between 9,000 and 11,000 nonsynonymous mutations. C, all tumors carried a nearly identical spectrum of mutations, with the majority C>G alterations. D, relative expression of MGMT by RNA sequencing across each tumor. Tanner M. Johanns et al. Cancer Discov 2016;6: ©2016 by American Association for Cancer Research

Download ppt "Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in."

Similar presentations

Teaching NeuroImages Neurology Resident and Fellow Section © 2013 American Academy of Neurology An unusual cause of conus medullaris syndrome.

Teaching NeuroImages Neurology Resident and Fellow Section © 2013 American Academy of Neurology An unusual cause of conus medullaris syndrome.
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Advances in Translational Research in Neuro-oncology.

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Advances in Translational Research in Neuro-oncology.
Genome evolution within the individual

Genome evolution within the individual
Sarah Leary, MD MS CBTTC 5/25/2016

Sarah Leary, MD MS CBTTC 5/25/2016
Figure 1 Sequence chromatograms of DNA isolated from two patients with sporadic KIT/PDGFRA wild-type gastrointestinal stromal tumors. A ) Region harboring.

Figure 1 Sequence chromatograms of DNA isolated from two patients with sporadic KIT/PDGFRA wild-type gastrointestinal stromal tumors. A ) Region harboring.
Enhanced DNA damage in IDH1 mutant glioma cells.

Enhanced DNA damage in IDH1 mutant glioma cells.
IDH1 mutant glioma cells are sensitive to TMZ

IDH1 mutant glioma cells are sensitive to TMZ
Overview of next-generation sequencing, neoantigen prediction, and functional T-cell analyses. Overview of next-generation sequencing, neoantigen prediction,

Overview of next-generation sequencing, neoantigen prediction, and functional T-cell analyses. Overview of next-generation sequencing, neoantigen prediction,
Summary of genetic alterations in resistant biopsies among patients progressing on ceritinib or alectinib. Summary of genetic alterations in resistant.

Summary of genetic alterations in resistant biopsies among patients progressing on ceritinib or alectinib. Summary of genetic alterations in resistant.
Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.

Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.
A, baseline and 4-week PET scan from patient 2 (MET c

A, baseline and 4-week PET scan from patient 2 (MET c
Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.

Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.
Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.
Intrinsic and acquired trastuzumab resistance.

Intrinsic and acquired trastuzumab resistance.
Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.
(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.

(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.
Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.
Figure 1 Mutations in SPG7 in a family with primary lateral sclerosis

Figure 1 Mutations in SPG7 in a family with primary lateral sclerosis

Similar presentations

Ads by Google